Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Oklahoma Attorney General Gentner Drummond Office on Wednesday confirmed action is in order with the Food and Drug Administration (FDA) addressing counterfeit weight-loss drug makers.

Dr. Kristen Kells, founder of Colorado Springs’ largest weight loss clinic, shared insights on GLP-1 drugs and explained why the Dr. Kells Method can offer better long-term ...

Dr. Kristen Kells discusses the pros and cons of GLP-1 drugs and why the Dr. Kells Method works so well for lasting results.

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...